{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T12:18:28Z","timestamp":1780575508299,"version":"3.54.1"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2021,9,3]],"date-time":"2021-09-03T00:00:00Z","timestamp":1630627200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,9,3]],"date-time":"2021-09-03T00:00:00Z","timestamp":1630627200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-021-00545-w","type":"journal-article","created":{"date-parts":[[2021,9,3]],"date-time":"2021-09-03T19:02:45Z","timestamp":1630695765000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["A phase 1b dose-escalation\/expansion study of BET inhibitor RO6870810 in patients with advanced multiple myeloma"],"prefix":"10.1038","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3385-3707","authenticated-orcid":false,"given":"Karthik","family":"Ramasamy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4165-6869","authenticated-orcid":false,"given":"Ajay","family":"Nooka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Quach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myo","family":"Htut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh","family":"Popat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela","family":"Liedtke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2109-1573","authenticated-orcid":false,"given":"Sascha A.","family":"Tuchman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7565-2052","authenticated-orcid":false,"given":"Jacob","family":"Laubach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Gasparetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asher","family":"Chanan-Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Hertzberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"deMario","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eveline","family":"Nueesch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelyne","family":"Chesne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izolda","family":"Franjkovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Lechner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3502-928X","authenticated-orcid":false,"given":"Martin","family":"Kornacker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hearn Jay","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,3]]},"reference":[{"key":"545_CR1","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.drudis.2017.09.011","volume":"23","author":"M Ramadoss","year":"2018","unstructured":"Ramadoss M, Mahadevan V. Targeting the cancer epigenome: synergistic therapy with bromodomain inhibitors. Drug Disco Today. 2018;23:76\u201389.","journal-title":"Drug Disco Today"},{"key":"545_CR2","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.cell.2011.08.017","volume":"146","author":"JE Delmore","year":"2011","unstructured":"Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, Jacobs HM, et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell. 2011;146:904\u201317.","journal-title":"Cell"},{"key":"545_CR3","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.cell.2013.03.036","volume":"153","author":"J Lov\u00e9n","year":"2013","unstructured":"Lov\u00e9n J, Hoke HA, Lin CY, Lau A, Orlando DA, Vakoc CR, et al. Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell. 2013;153:320\u201334.","journal-title":"Cell"},{"key":"545_CR4","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/nrd4286","volume":"13","author":"P Filippakopoulos","year":"2014","unstructured":"Filippakopoulos P, Knapp S. Targeting bromodomains: epigenetic readers of lysine acetylation. Nat Rev Drug Disco. 2014;13:337\u201356.","journal-title":"Nat Rev Drug Disco"},{"key":"545_CR5","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s11912-019-0762-x","volume":"21","author":"S Genta","year":"2019","unstructured":"Genta S, Pirosa MC, Stathis A. BET and EZH2 Inhibitors: novel approaches for targeting cancer. Curr Oncol Rep. 2019;21:13.","journal-title":"Curr Oncol Rep."},{"key":"545_CR6","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.3390\/cancers11101483","volume":"11","author":"D Reyes-Garau","year":"2019","unstructured":"Reyes-Garau D, Ribeiro ML, Rou\u00e9 G. Pharmacological targeting of BET bromodomain proteins in acute myeloid leukemia and malignant lymphomas: from molecular characterization to clinical applications. Cancers. 2019;11:1483.","journal-title":"Cancers"},{"key":"545_CR7","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/s41573-019-0030-7","volume":"18","author":"AG Cochran","year":"2019","unstructured":"Cochran AG, Conery AR, Sims RJ. Bromodomains: a new target class for drug development. Nat Rev Drug Disco. 2019;18:609\u201328.","journal-title":"Nat Rev Drug Disco"},{"key":"545_CR8","doi-asserted-by":"crossref","unstructured":"Roboz GJ, Desai P, Lee S, Ritchie EK, Winer ES, DeMario M, et al. A dose escalation study of RO6870810\/TEN-10 in patients with acute myeloid leukemia and myelodysplastic syndrome. Leuk Lymphoma. 2021; 1\u201313. [published online ahead of print]","DOI":"10.1080\/10428194.2021.1881509"},{"key":"545_CR9","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1038\/s41416-020-01180-1","volume":"124","author":"GI Shapiro","year":"2021","unstructured":"Shapiro GI, LoRusso P, Dowlati A, Do TK, Jacobson CA, Vaishampayan U, et al. A phase 1 study of RO6870810, a novel bromodomain and extra-terminal protein inhibitor, in patients with NUT carcinoma, other solid tumours, or diffuse large B-cell lymphoma. Br J Cancer. 2021;124:744\u201353.","journal-title":"Br J Cancer"},{"key":"545_CR10","doi-asserted-by":"publisher","first-page":"e196","DOI":"10.1016\/S2352-3026(16)00021-1","volume":"3","author":"S Amorim","year":"2016","unstructured":"Amorim S, Stathis A, Gleeson M, Iyengar S, Magarotto V, Leleu X, et al. Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study. Lancet Haematol. 2016;3:e196\u2013204.","journal-title":"Lancet Haematol"},{"key":"545_CR11","doi-asserted-by":"publisher","unstructured":"Ramasamy K, Gay F, Weisel K, Zweegman S, Mateos MV, Richardson P, et al. Improving outcomes for patients with relapsed multiple myeloma: Challenges and considerations of current and emerging treatment options. Blood Rev. 2021;49:100808. https:\/\/doi.org\/10.1016\/j.blre.2021.100808.","DOI":"10.1016\/j.blre.2021.100808"},{"key":"545_CR12","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1093\/annonc\/mdx157","volume":"28","author":"DB Doroshow","year":"2017","unstructured":"Doroshow DB, Eder JP, LoRusso PM. BET inhibitors: a novel epigenetic approach. Ann Oncol. 2017;28:1776\u201387.","journal-title":"Ann Oncol"},{"key":"545_CR13","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1038\/onc.2015.245","volume":"35","author":"R Gopalakrishnan","year":"2016","unstructured":"Gopalakrishnan R, Matta H, Tolani B, Triche T Jr, Chaudhary PM. Immunomodulatory drugs target IKZF1-IRF4-MYC axis in primary effusion lymphoma in a cereblon-dependent manner and display synergistic cytotoxicity with BRD4 inhibitors. Oncogene. 2016;35:1797\u2013810.","journal-title":"Oncogene"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-021-00545-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-021-00545-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-021-00545-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T18:22:52Z","timestamp":1669918972000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-021-00545-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,3]]},"references-count":13,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2021,9]]}},"alternative-id":["545"],"URL":"https:\/\/doi.org\/10.1038\/s41408-021-00545-w","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,3]]},"assertion":[{"value":"4 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"K.R.: Janssen: Consultancy, Honoraria, Membership on an entity\u2019s Board of Directors or advisory committees, Research Funding, Speakers Bureau; BMS: Consultancy, Research Funding, Speakers Bureau; Takeda: Consultancy, Research Funding, Speakers Bureau; Amgen: Consultancy, Honoraria, Research Funding; Abbvie: Consultancy, Honoraria; Sanofi: Consultancy, Honoraria; Oncopeptides: Consultancy, Honoraria. A.N.: Adaptive Technologies: Consultancy, Honoraria; Oncopeptides: Consultancy, Honoraria; Spectrum Pharmaceuticals: Consultancy; GlaxoSmithKline: Consultancy, Honoraria, Other: Personal Fees: Travel\/accommodations\/expenses, Research Funding; Takeda: Consultancy, Honoraria, Research Funding; Celgene: Consultancy, Honoraria, Research Funding; Janssen: Consultancy, Honoraria, Research Funding; Amgen: Consultancy, Honoraria, Research Funding; Bristol Myers Squibb: Consultancy, Honoraria, Research Funding; Sanofi: Consultancy, Honoraria; Karyopharm Therapeutics, Adaptive technologies: Consultancy, Honoraria, Research Funding. H.Q.: Amgen, Celgene, Karyopharm, GSK, Janssen Cilag, Sanofi.: Membership on an entity\u2019s Board of Directors or advisory committees; GlaxoSmithKline, Karyopharm, Amgen, Celgene, Janssen Cilag: Consultancy; GlaxoSmithKline, Karyopharm, Amgen, Celgene, Janssen Cilag: Honoraria; Amgen, Sanofi, Celgene, Karyopharm, GSK: Research Funding. M.H.: City of Hope Medical Center: Current Employment. R.P.: AbbVie: Consultancy, Honoraria; Celgene: Consultancy, Honoraria; Takeda: Consultancy, Honoraria, Other: Travel support, Research Funding; Bristol Myers Squibb: Consultancy, Honoraria; GSK: Consultancy, Honoraria, Other: TRAVEL, ACCOMMODATIONS, EXPENSES (paid by any for-profit health care company); Janssen: Consultancy, Honoraria, Other: TRAVEL, ACCOMMODATIONS, EXPENSES (paid by any for-profit health care company). M.L.: Jazz Pharmaceuticals: Membership on an entity\u2019s Board of Directors or advisory committees; GSK: Membership on an entity\u2019s Board of Directors or advisory committees; Pfizer: Honoraria; Janssen: Membership on an entity\u2019s Board of Directors or advisory committees; Celgene: Membership on an entity\u2019s Board of Directors or advisory committees; Caelum: Membership on an entity\u2019s Board of Directors or advisory committees; Adaptive: Membership on an entity\u2019s Board of Directors or advisory committees. S.A.T.: Caelum: Honoraria; Sanofi: Honoraria, Research Funding; Amgen: Research Funding; Janssen: Research Funding; Oncopeptides: Consultancy; Roche: Research Funding; Karyopharm: Honoraria, Research Funding; Celgene: Honoraria, Research Funding, Speakers Bureau. J.L.: nothing to disclose. C.G.: nothing to disclose. A.C.-K.: nothing to disclose. M.H.: Gilead: Membership on an entity\u2019s Board of Directors or advisory committees; MSD: Membership on an entity\u2019s Board of Directors or advisory committees; Abbvie: Honoraria; BMS: Honoraria; Takeda: Honoraria, Membership on an entity\u2019s Board of Directors or advisory committees; Janssen: Honoraria, Membership on an entity\u2019s Board of Directors or advisory committees; Roche: Honoraria, Membership on an entity\u2019s Board of Directors or advisory committees, Other: Support of parent study and funding of editorial support. M.d.M.: BioNTech SE: Current Employment, Current equity holder in the publicly-traded company; Hoffmann-La Roche Ltd.: Current equity holder in a publicly-traded company, Ended employment in the past 24 months. E.N.: Hoffmann-La Roche Ltd.: Current Employment, Current equity holder in the publicly-traded company. E.C.: Hoffmann-La Roche Ltd.: Current Employment, Current equity holder in the publicly-traded company. I.F.: Hoffmann-La Roche Ltd.: Current Employment, Current equity holder in the publicly-traded company. K.L.: Roche Diagnostics GmbH: Current Employment, Current equity holder in the publicly-traded company. M.K.: Hoffmann-La Roche Ltd.: Current Employment, Current equity holder in the publicly-traded company. H.J.C.: Paid employee of the MMRF; research funding from Takeda, Celgene, and Genentech.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"149"}}